John Cosachov, DO
Allergy & Immunology · Auburn, NYNPI 1932207370
Payments from drug & device makers
Across 203 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$593
- Novartis$283
- Alk-abello, Inc$191
- Regeneron Healthcare Solutions, Inc.$165
- ARS Pharmaceuticals Operations, Inc.$156
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,70699%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 76 | $1,196 |
| AstraZeneca | 34 | $593 |
| Novartis | 16 | $283 |
| Alk-abello, Inc | 5 | $191 |
| Regeneron Healthcare Solutions, Inc. | 5 | $165 |
| ARS Pharmaceuticals Operations, Inc. | 9 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $150 |
| Optinose US, Inc. | 7 | $133 |
| Sanofi | 5 | $95 |
| Pfizer | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 5 | $74 |
| Biocryst US Sales Co., LLC | 3 | $69 |
| Boehringer Ingelheim | 3 | $69 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| Bayer | 2 | $68 |
| USWM, LLC | 2 | $44 |
| CSL Behring | 2 | $43 |
| Blueprint Medicines Corporation | 2 | $42 |
| Grifols USA, LLC | 2 | $38 |
| Genentech USA, Inc. | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Shire North American Group Inc | 2 | $26 |
| Amgen | 1 | $20 |
| Biocryst Pharmaceuticals, Inc. | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Odactra$122
How this compares
$3,746 in reported general payments places this provider in the 50th percentile of 320 allergy & immunology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 46 | $21,537 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $17,827 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $15,533 |
| Arnuity ElliptaFluticasone Furoate | 34 | $12,462 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $10,364 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $9,456 |
| Epinephrine | 33 | $7,941 |
| DuleraMometasone/Formoterol | 13 | $6,549 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $4,529 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 142 | $3,929 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $3,424 |
| Mometasone Furoate | 20 | $3,276 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $2,303 |
| Ipratropium Bromide | 61 | $1,748 |
| Montelukast Sodium | 164 | $1,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,196 | $61,282119 claims |
| AstraZenecaSymbicort | $593 | $15,53342 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $7,94133 claims |
| MerckDulera | $15 | $6,54913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 320 allergy & immunology providers in New York.
Other allergy & immunology in Auburn
- Peter DeaneRochester$3.7M
- Syed MustafaRochester$3.6M
- Golda HudesBronx$2.4M
- Arye RubinsteinBronx$1.1M
- Ujwala KazaNew York$1.1M
- Robert SporterNew York$980K
- Mili ShumWest Harrison$924K
- Paula BusseNew York$821K
- Gregory PuglisiPlainview$813K
- Stanley GoldsteinRockville Centre$653K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.